Clinical Laboratory

You have to be registered and logged in for purchasing articles.

Abstract	Development of a High Throughput Single Nucleotide Polymorphism Screening Method for the Cytochrome P450 1A2 Polymorphisms CYP1A21C and CYP1A21F Are they Useful as Predictive Markers in Mental Disorders? by Marco Klemm, Moritz Eidens, Marion Lorenz, Stefan Prause, Alexander Weise, Norbert Dahmen, Thomas Forst, Andreas Pfützner

	Background: The cytochrome P450 1A2 (CYP1A2) gene encodes one of the most important enzymes of the Phase I drug metabolism, which is involved in the metabolism of many lipophilic xenobiotics, such as haloperidol, theophylline, phenacetine, and others. The recently discovered single nucleotide polymorphisms CYP1A21C (- 3860G→A) in the 5’ flanking region of the gene and CYP1A21F (-163C→A) in intron 1 seem to interfere with the expression rate or catalytic function of the enzyme. Polymorphism carriers may either have a risk of reduced drug degradation and side effects, or may present with an increased induction of enzymatic activity resulting in clinical non-response to the prescribed therapy. We investigated two populations, a mental disease group and a healthy control group, to identify whether these two genetic variants are correlated with the general development of a mental disorder and if they could potentially be used as predictive markers for manifestation of the same. Methods: Using specifically designed primers, we established a high-throughput multiplex screening realtime PCR method for the two polymorphisms on the CYP1A2 gene with the Roche LightCycler® instrument. Results: We analysed the two cohorts to identify whether one of the two described genetic variants may be associated with the manifestation of a mental disorder in general. For the CYP1A21C variant, we identified an allele frequency of 1.7 % for both cohorts. For the CYP1A1F polymorphism, we found an allele frequency of 74.5 % for the mental disease group and 68.6 % for the healthy control group. Conclusions: This new diagnostic method of multiplex detection may be helpful to routinely identify carriers of CYP1A2 variants and to improve the therapeutic effectiveness by selection of the most appropriate therapeutic regimen. As a result of this pilot study, there appeared to be no significant correlation between the existence of one of the investigated genetic variants and the development of a mental disorder. DOI: Clin. Lab. 2010;56:473-480

Abstract